Literature DB >> 25595803

A game of numbers: the stoichiometry of antibody-mediated neutralization of flavivirus infection.

Theodore C Pierson1, Michael S Diamond2.   

Abstract

The humoral response contributes to the protection against viral pathogens. Although antibodies have the potential to inhibit viral infections via several mechanisms, an ability to neutralize viruses directly may be particularly important. Neutralizing antibody titers are commonly used as predictors of protection from infection, especially in the context of vaccine responses and immunity. Despite the simplicity of the concept, how antibody binding results in virus inactivation is incompletely understood despite decades of research. Flaviviruses have been an attractive system in which to seek a structural and quantitative understanding of how antibody interactions with virions modulate infection because of the contribution of antibodies to both protection and pathogenesis. This review will present a stoichiometric model of antibody-mediated neutralization of flaviviruses and discuss how these concepts can inform the development of vaccines and antibody-based therapeutics.
© 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibody; Enhancement; Flavivirus; Maturation; Neutralization; Pathogenesis; Protection; Stoichiometry; Vaccine

Mesh:

Substances:

Year:  2014        PMID: 25595803      PMCID: PMC4910618          DOI: 10.1016/bs.pmbts.2014.10.005

Source DB:  PubMed          Journal:  Prog Mol Biol Transl Sci        ISSN: 1877-1173            Impact factor:   3.622


  120 in total

1.  Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components.

Authors:  Krystyna Mozdzanowska; Jingqi Feng; Mark Eid; Darya Zharikova; Walter Gerhard
Journal:  Virology       Date:  2006-06-14       Impact factor: 3.616

2.  Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody.

Authors:  Mickaël V Cherrier; Bärbel Kaufmann; Grant E Nybakken; Shee-Mei Lok; Julia T Warren; Beverly R Chen; Christopher A Nelson; Victor A Kostyuchenko; Heather A Holdaway; Paul R Chipman; Richard J Kuhn; Michael S Diamond; Michael G Rossmann; Daved H Fremont
Journal:  EMBO J       Date:  2009-08-27       Impact factor: 11.598

Review 3.  Molecular mechanisms involved in the early steps of flavivirus cell entry.

Authors:  Bärbel Kaufmann; Michael G Rossmann
Journal:  Microbes Infect       Date:  2010-12-10       Impact factor: 2.700

4.  Monoclonal anti-Fc receptor IgG blocks antibody enhancement of viral replication in macrophages.

Authors:  J S Peiris; S Gordon; J C Unkeless; J S Porterfield
Journal:  Nature       Date:  1981-01-15       Impact factor: 49.962

5.  Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype.

Authors:  W W Shanaka I Rodrigo; Olivia K T Block; Christopher Lane; Soila Sukupolvi-Petty; Ana P Goncalvez; Syd Johnson; Michael S Diamond; Ching-Juh Lai; Robert C Rose; Xia Jin; Jacob J Schlesinger
Journal:  Virology       Date:  2009-10-14       Impact factor: 3.616

6.  Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model.

Authors:  John D Morrey; Venkatraman Siddharthan; Aaron L Olsen; Hong Wang; Justin G Julander; Jeffery O Hall; Hua Li; Jeffrey L Nordstrom; Scott Koenig; Syd Johnson; Michael S Diamond
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

Review 7.  Evolutionary and ecological factors underlying the tempo and distribution of yellow fever virus activity.

Authors:  Christine V F Carrington; Albert J Auguste
Journal:  Infect Genet Evol       Date:  2012-09-03       Impact factor: 3.342

Review 8.  Dengue virus vaccine development.

Authors:  Lauren E Yauch; Sujan Shresta
Journal:  Adv Virus Res       Date:  2014       Impact factor: 9.937

Review 9.  Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes.

Authors:  Scott B Halstead; Suresh Mahalingam; Mary A Marovich; Sukathida Ubol; David M Mosser
Journal:  Lancet Infect Dis       Date:  2010-10       Impact factor: 25.071

10.  A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface.

Authors:  Guntur Fibriansah; Joanne L Tan; Scott A Smith; Adamberage R de Alwis; Thiam-Seng Ng; Victor A Kostyuchenko; Kristie D Ibarra; Jiaqi Wang; Eva Harris; Aravinda de Silva; James E Crowe; Shee-Mei Lok
Journal:  EMBO Mol Med       Date:  2014-01-13       Impact factor: 12.137

View more
  21 in total

Review 1.  Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity.

Authors:  Laura A VanBlargan; Leslie Goo; Theodore C Pierson
Journal:  Microbiol Mol Biol Rev       Date:  2016-10-26       Impact factor: 11.056

2.  A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection.

Authors:  Nurgun Kose; Julie M Fox; Gopal Sapparapu; Robin Bombardi; Rashika N Tennekoon; A Dharshan de Silva; Sayda M Elbashir; Matthew A Theisen; Elisabeth Humphris-Narayanan; Giuseppe Ciaramella; Sunny Himansu; Michael S Diamond; James E Crowe
Journal:  Sci Immunol       Date:  2019-05-17

3.  Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype.

Authors:  Kimberly A Dowd; Christina R DeMaso; Rebecca S Pelc; Scott D Speer; Alexander R Y Smith; Leslie Goo; Derek J Platt; John R Mascola; Barney S Graham; Mark J Mulligan; Michael S Diamond; Julie E Ledgerwood; Theodore C Pierson
Journal:  Cell Rep       Date:  2016-07-29       Impact factor: 9.423

Review 4.  Mapping the diverse structural landscape of the flavivirus antibody repertoire.

Authors:  Madhumati Sevvana; Richard J Kuhn
Journal:  Curr Opin Virol       Date:  2020-08-13       Impact factor: 7.090

5.  Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human Antibodies.

Authors:  Ellen Young; Robert H Carnahan; Daniela V Andrade; Nurgun Kose; Rachel S Nargi; Ethan J Fritch; Jennifer E Munt; Michael P Doyle; Laura White; Thomas J Baric; Mark Stoops; Aravinda DeSilva; Longping V Tse; David R Martinez; Deanna Zhu; Stefan Metz; Marcus P Wong; Diego A Espinosa; Magelda Montoya; Scott B Biering; Soila Sukulpolvi-Petty; Guillermina Kuan; Angel Balmaseda; Michael S Diamond; Eva Harris; James E Crowe; Ralph S Baric
Journal:  Cell Host Microbe       Date:  2020-05-13       Impact factor: 21.023

Review 6.  Flavivirus structural heterogeneity: implications for cell entry.

Authors:  Félix A Rey; Karin Stiasny; Franz X Heinz
Journal:  Curr Opin Virol       Date:  2017-07-03       Impact factor: 7.090

7.  Impact of Pre-exposure History and Host Genetics on Antibody Avidity Following Norovirus Vaccination.

Authors:  Lisa C Lindesmith; Michael L Mallory; Taylor A Jones; Charles Richardson; Robert R Goodwin; Frank Baehner; Paul M Mendelman; Robert F Bargatze; Ralph S Baric
Journal:  J Infect Dis       Date:  2017-03-15       Impact factor: 5.226

8.  Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains.

Authors:  James Brett Case; Samantha Mackin; John M Errico; Zhenlu Chong; Emily A Madden; Bradley Whitener; Barbara Guarino; Michael A Schmid; Kim Rosenthal; Kuishu Ren; Ha V Dang; Gyorgy Snell; Ana Jung; Lindsay Droit; Scott A Handley; Peter J Halfmann; Yoshihiro Kawaoka; James E Crowe; Daved H Fremont; Herbert W Virgin; Yueh-Ming Loo; Mark T Esser; Lisa A Purcell; Davide Corti; Michael S Diamond
Journal:  Nat Commun       Date:  2022-07-02       Impact factor: 17.694

9.  In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains.

Authors:  Michael Diamond; Rita Chen; Emma Winkler; James Case; Ishmael Aziati; Traci Bricker; Astha Joshi; Tamarand Darling; Baoling Ying; John Errico; Swathi Shrihari; Laura VanBlargan; Xuping Xie; Pavlo Gilchuk; Seth Zost; Lindsay Droit; Zhuoming Liu; Spencer Stumpf; David Wang; Scott Handley; W Stine; Pei-Yong Shi; Miguel Garcia-Knight; Raul Andino; Charles Chiu; Ali Ellebedy; Daved Fremont; Sean Whelan; James Crowe; Lisa Purcell; Davide Corti; Andrianus Boon
Journal:  Res Sq       Date:  2021-04-23

10.  Near-germline human monoclonal antibodies neutralize and protect against multiple arthritogenic alphaviruses.

Authors:  Ryan J Malonis; James T Earnest; Arthur S Kim; Matthew Angeliadis; Frederick W Holtsberg; M Javad Aman; Rohit K Jangra; Kartik Chandran; Johanna P Daily; Michael S Diamond; Margaret Kielian; Jonathan R Lai
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.